Skin cancer, effect of cannabinoids in animal models
| Disease model | Treatment | Comparator | Results | Ref. |
|---|---|---|---|---|
| Athymic nude mice, BRAF wild-type melanoma xenografts | THC (15 mg/kg per day p.o. for 20 days | Vehicle; THC-CBD (extract, ~7.5 + 7.5 mg/kg per day, p.o.); TMZ 5 mg/kg p.o. per day, 20 days | THC and CBD + THC (extract) signif. inhibited xenograft growth and were more effective than TMZ (order: CBD + THC > THC > TMZ > vehicle) | [143] |
| B16 melanoma; C57BL/6 wild-type mice and CB1/CB2 deficient mice | THC 5 mg /kg per day s.c., 25 days | Vehicle | THC inhibits HCmel12 melanoma growth but does not affect B16 and CB1/CB2 deficient Hcmel12 | [146] |
| A2058 s.c. xenograft, male NOD scid gamma (NSG) mice | CBD 10 mg/kg + THC 10 mg/kg s.c. per day b.w. for 21 days | Vehicle only, MEKi (0.75 mg/kg per day) CBD + THC + MEKi | All three treatments showed a signif. reduction in tumour volume and in tumour area as compared to vehicle, without a statistically signif. difference between groups (CBD + THC vs. MEKi, MEKi vs. CBD + THC + MEKi, CBD + THC vs. CBD + THC + MEKi); MEKi alone reduced tumour mass more efficiently than CBD + THC | [144] |
| Murine B16F10 melanoma tumours, C57BL/6 mice | CBD (5 mg/kg i.p., twice weekly) | Control; cisplatin (i.p), 5 mg/kg once weekly | Increased the survival and reduced tumour size as compared to controls, although less than cisplatin; quality of life and movement of CBD-treated mice were better than with cisplatin | [147] |
MEKi: mitogen-activated protein kinase inhibitor trametinib; signif.: significant; p.o.: per os; ~: about